KB (Eagle) cell culture has played a powerful role in discovery of antitumor agents from higher plants. Had KB alone been used as a preliminary screen, with in vivo screening limited to KB-active extracts, fractions, or compounds, KB activity of crude products would have led to discovery of vinblastine, vincristine, podophyllotoxin (from which the semisynthetics VM-26 and VP-16 were derived), and all but one of the antitumor agents now under development toward or in clinical evaluation, including bouvardin, bruceantin, camptothecin, ellipticine, homoharringtonine, maytansine, taxol, thalicarpine, and tripdiolide. Indicine N-oxide is the only important antitumor agent which would have been discovered only by in vivo screening of crude plant products. A substantial number of compounds effective against lymphoid leukemia L1210 and B16 melanoma were isolated from plants, extracts of which were active against KB.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/np50022a010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unanchored simulated treatment comparison on survival outcomes using parametric and Royston-Parmar models with application to lenvatinib plus pembrolizumab in renal cell carcinoma.
BMC Med Res Methodol
January 2025
Clifton Insight, Bristol, UK.
Background: Population-adjusted indirect comparison using parametric Simulated Treatment Comparison (STC) has had limited application to survival outcomes in unanchored settings. Matching-Adjusted Indirect Comparison (MAIC) is commonly used but does not account for violation of proportional hazards or enable extrapolations of survival. We developed and applied a novel methodology for STC in unanchored settings.
View Article and Find Full Text PDFOncolytic reprogramming of tumor microenvironment shapes CD4 T-cell memory via the IL6ra-Bcl6 axis for targeted control of glioblastoma.
Nat Commun
January 2025
Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Oncolytic viruses (OVs) emerge as a promising cancer immunotherapy. However, the temporal impact on tumor cells and the tumor microenvironment, and the nature of anti-tumor immunity post-therapy remain largely unclear. Here we report that CD4 T cells are required for durable tumor control in syngeneic murine models of glioblastoma multiforme after treatment with an oncolytic herpes simplex virus (oHSV) engineered to express IL-12.
View Article and Find Full Text PDFCharacterization of human alcohol dehydrogenase 4 and aldehyde dehydrogenase 2 as enzymes involved in the formation of 5-carboxylpirfenidone, a major metabolite of pirfenidone.
Drug Metab Dispos
January 2025
Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Japan; WPI Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kakuma-machi, Kanazawa, Japan.
Pirfenidone (PIR) is used in the treatment of idiopathic pulmonary fibrosis. After oral administration, it is metabolized by cytochrome P450 1A2 to 5-hydroxylpirfenidone (5-OH PIR) and further oxidized to 5-carboxylpirfenidone (5-COOH PIR), a major metabolite excreted in the urine (90% of the dose). This study aimed to identify enzymes that catalyze the formation of 5-COOH PIR from 5-OH PIR in the human liver.
View Article and Find Full Text PDFCommon Oncologic Wounds.
Nurs Clin North Am
March 2025
Conway School of Nursing, The Catholic University of America, Washington, DC, USA; Inova Health System, Falls Church, VA, USA. Electronic address:
This article presents clinically focused, evidence-based summary of common wounds and alterations in tissue/skin associated with oncologic treatment, with a focus on risk factors, identification, prevention, and management of acute radiation dermatitis and chemotherapy-induced extravasation.
View Article and Find Full Text PDFSafety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study.
RMD Open
January 2025
Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany.
Objectives: DARWIN 3 (ClinicalTrials.gov: NCT02065700) assessed the safety and efficacy of filgotinib in a long-term extension (LTE) of two phase II randomised controlled rheumatoid arthritis (RA) trials.
Methods: Eligible patients completing the 24-week DARWIN 1 (filgotinib plus methotrexate) and DARWIN 2 (filgotinib monotherapy) trials could enrol.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!